These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25100389)

  • 21. Pregnancy Outcomes and Insulin Requirements in Women with Type 1 Diabetes Treated with Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections: Cohort Study.
    Abell SK; Suen M; Pease A; Boyle JA; Soldatos G; Regan J; Wallace EM; Teede HJ
    Diabetes Technol Ther; 2017 May; 19(5):280-287. PubMed ID: 28282241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Islet Transplantation Provides Superior Glycemic Control With Less Hypoglycemia Compared With Continuous Subcutaneous Insulin Infusion or Multiple Daily Insulin Injections.
    Holmes-Walker DJ; Gunton JE; Hawthorne W; Payk M; Anderson P; Donath S; Loudovaris T; Ward GM; Kay TW; OʼConnell PJ
    Transplantation; 2017 Jun; 101(6):1268-1275. PubMed ID: 27490410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study.
    Šoupal J; Petruželková L; Grunberger G; Hásková A; Flekač M; Matoulek M; Mikeš O; Pelcl T; Škrha J; Horová E; Škrha J; Parkin CG; Svačina Š; Prázný M
    Diabetes Care; 2020 Jan; 43(1):37-43. PubMed ID: 31530663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous subcutaneous insulin infusion does not correspond with pregnancy outcomes despite better glycemic control as compared to multiple daily injections in type 1 diabetes - Significance of pregnancy planning and prepregnancy HbA1c.
    Żurawska-Kliś M; Kosiński M; Kuchnicka A; Rurka M; Hałucha J; Wójcik M; Cypryk K
    Diabetes Res Clin Pract; 2021 Feb; 172():108628. PubMed ID: 33358970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID Study.
    Blevins T; Lane W; Rodbard D; Sindelar D; Fan L; Ellinor K; Ilag L; Ly T; Johnson J
    Diabetes Technol Ther; 2021 Jan; 23(1):51-58. PubMed ID: 32631081
    [No Abstract]   [Full Text] [Related]  

  • 26. The dawn phenomenon revisited: implications for diabetes therapy.
    Carroll MF; Schade DS
    Endocr Pract; 2005; 11(1):55-64. PubMed ID: 16033737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.
    Raskin P; Bode BW; Marks JB; Hirsch IB; Weinstein RL; McGill JB; Peterson GE; Mudaliar SR; Reinhardt RR
    Diabetes Care; 2003 Sep; 26(9):2598-603. PubMed ID: 12941725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Effectiveness of Continuous Subcutaneous Insulin Infusion in the Prevention of Hypoglycemia in Adults with Type 1 Diabetes.
    Summers JC; Briganti EM; Fitzgerald ZA; Lambers LNJ; Cohen ND
    Diabetes Technol Ther; 2019 Aug; 21(8):423-429. PubMed ID: 31180239
    [No Abstract]   [Full Text] [Related]  

  • 29. The Effect of Prestudy Insulin Therapy on Safety and Efficacy of Human Regular U-500 Insulin by Pump or Injection: A Posthoc Analysis.
    Hood RC; Chen Y; Sindelar DK; Ly T; Juneja R; Pollom RD; Ilag L; Wysham C
    Endocr Pract; 2021 Aug; 27(8):783-789. PubMed ID: 33515757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of Ramadan fasting in young patients with type 1 diabetes: A systematic review and meta-analysis.
    Loh HH; Lim LL; Loh HS; Yee A
    J Diabetes Investig; 2019 Nov; 10(6):1490-1501. PubMed ID: 30938074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes.
    Farrar D; Tuffnell DJ; West J; West HM
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005542. PubMed ID: 27272351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of multiple daily insulin therapy with continuous subcutaneous insulin infusion therapy in adolescents with type 1 diabetes mellitus: a single-center experience from Turkey.
    Abaci A; Atas A; Unuvar T; Demir K; Bober E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 2009 Jun; 22(6):539-45. PubMed ID: 19694201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weight in adolescents with type 1 diabetes mellitus during continuous subcutaneous insulin infusion (CSII) therapy.
    Raile K; Noelle V; Landgraf R; Schwarz HP
    J Pediatr Endocrinol Metab; 2002 May; 15(5):607-12. PubMed ID: 12014519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
    Rubin RR; Peyrot M
    J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RT-CGM in conjunction with CSII vs MDI in optimizing glycaemic control in T1DM: Systemic review and meta-analysis.
    William J; McCluskey J; Gleeson N
    Endocrinol Diabetes Metab; 2022 Mar; 5(2):e00324. PubMed ID: 35118826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Metabolic control in young children with type 1 diabetes treated with continuous subcutaneous insulin infusion (insulin pump)].
    Pańkowska E; Lipka M; Wysocka M; Szypowska A; Trippenbach-Dulska H; Czaplińska M; Kołodziejska B
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2003; 9(1):11-5. PubMed ID: 12831632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes.
    Bode BW; Steed RD; Davidson PC
    Diabetes Care; 1996 Apr; 19(4):324-7. PubMed ID: 8729154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.
    Boland EA; Grey M; Oesterle A; Fredrickson L; Tamborlane WV
    Diabetes Care; 1999 Nov; 22(11):1779-84. PubMed ID: 10546007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.